BridgeBio Pharma (BBIO) Treasury Shares (2018 - 2026)

BridgeBio Pharma has reported Treasury Shares for 7 years, with the latest figure at $405.8 million in Q1 2026.

• Quarterly Treasury Shares rose 25.52% year-over-year to $405.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $405.8 million (up 25.52% YoY) and the FY2025 annual result came in at $323.3 million, up 17.55% from the prior year.
• Treasury Shares improved to $405.8 million in Q1 2026 per BBIO's latest filing, from $323.3 million in the prior quarter.
• Over five years, Treasury Shares peaked at $10.9 million in Q1 2023 and troughed at $6.2 million in Q2 2022.
• A 5-year average of $7.4 million and a median of $6.9 million in 2022 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2022 and 2023: Treasury Shares jumped 5080.86% in 2022, then changed 0.0% in 2023.
• Over 5 years, Treasury Shares stood at $275.0 million in 2022, then changed by 0.0% to $275.0 million in 2023, then changed by 0.0% to $275.0 million in 2024, then grew by 17.55% to $323.3 million in 2025, then rose by 25.52% to $405.8 million in 2026.
• According to Business Quant data, Treasury Shares over the past three periods registered $405.8 million, $323.3 million, and $323.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.